

February 9, 2006

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Mail Stop: Information Disclosure Statement, P. O. Box 1450, Alexandria, VA 22313-1450.

	Christina Dueñas
	Name of Person Mailing Paper
February 9, 2006	a Po
Date of Deposit	Signature of Person Mailing Paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	f:)	Examiner: TBA
SMITH, Dan)	Group Art Unit: TBA
Serial No.: 10/550	,722)	Docket No.: 8114-009-WO-US
Filed: September 2	26, 2005)	Date Mailed: February 9, 2006
For: SELECTED I	RNA MOTIFS TO)	
INDUCE CE	LL DEATH AND/OR)	
APOPTOSIS)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Information Disclosure Statement Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

This document is an Information Disclosure Statement to the above-cited patent application and filed pursuant to 37 C.F.R. § 1.97(b)(3). Therefore, <u>no fee is</u> believed to be due.

Attached are forms PTO/SB/08A and PTO/SB/08B listing documents believed relevant to the subject application. The submission of this document is not intended, nor should it be construed, to constitute an admission that any patent, patent application, article, or other information referred to herein is "prior art" unless specifically designated as such. In fact, applicants submit that these documents do not affect the patentability of the subject invention. In accordance with 37 C.F.R. § 1.97(g), the filing of this information shall not be construed to represent that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is respectfully requested that the listing of documents in the attached forms be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication pursuant to the §609 of the Manual of Patent Examining Procedures (MPEP).

The order of the documents listed in the attached forms is to be accorded no particular import, as the order thereof is completely fortuitous. Additionally, the documents are not necessarily analogous art. A copy of each article document listed in the attached forms is enclosed.

It is believed that this disclosure complies with the requirements as set forth under 37 C.F.R. § 1.56, § 1.97, and § 1.98 and §707.05(b) of the MPEP. If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 so that any deficiencies can be remedied.

It is further believed that this Information Disclosure Statement is being submitted before the mailing of an Office Action on the merits. Accordingly, no fee is believed to be due under 37 C.F.R. § 197(b)(3). If an Office Action on the merits has in fact been mailed,

authorization is hereby given to charge the required fee of \$180.00 under 37 C.F.R. \$ 1.97(c)(2) and 1.17(p) to Deposit Account No. 502235.

Respectfully submitted,

Date: 2/9/04

David M. Kohn, J.D. Reg. No. 53,150

CATALYST LAW GROUP, APC 9710 Scranton Road, Suite 170 San Diego, California 92121 (858) 450-0099 (858) 450-9834 (Fax)

FEB 1 3 2006 w

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substill	TRAPE 49/PTO				Complete if Known
Oubstitue	7.0/1 10			Application Number	10/550,722
INFORMATION DISCLOSURE			CLOSURE	Filing Date	September 26, 2005
STA	TEMENT B	YA	PPLICANT	First Named Inventor	SMITH, Dan
(Use as many sheets as necessary)		Art Unit	TBD		
		Examiner Name	TBD		
Sheet	1	of	2	Attorney Docket Number	8114-009-WO-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ELBASHIR et al. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes and Development, 2000 Vol. 15:188-200.	
		WIANNY et al. Specific interference with gene function by double-stranded RNA in early mouse development. Nature Cell Biology, 2000 Vol. 2:70-75.	
		SVOBODA et al. Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. Development, 2000 Vol. 127:4147-4156.	
		ZELEZNICK et al. Treatment of Leukemic (L-1210) Mice with Double-stranded Polyribonucleotides. Proc Soc Exp Biol Med, 1969, Vol 130:126-128.	
		BRANCH, AD. A good antisense molecule is hard to find. TIBS, 1998 Vol. 23:45-50.	
		JEN et al. Supression of gene expression by targeted disruption of messenger RNA: Available options and current stratagies. Stem Cells, 2000 Vol. 18:307-319.	
17		OATES et al. Too much interference: Injection of double-stranded RAN has nonspecific effects in the zebrafish embryo. Development and Biology, 2000 Vol. 224:20-28.	
		COBURN, et al. siRNAs: a new wave of RNA-based therapeutics: Journal of Antimicrobial Chemotherapy, 2003 Vol. 51:753-756.	
		AGAMI A. RNAi and related mechanisms and thier potential use for therapy. Current Opinion in Chemical Biology, 2002 Vol. 6:829-83.	
		GREEN et al. Antisense Oligonucleotides: An evolving technology for the modulation of gene expression in human disease. J Am Coll Surg, 2000 Vol. 191:93-105.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO				Complete if Known			
Oubstitu	325334410 10/10/11/1443/1 10		Application Number	10/550,722				
INF	ORMATION	I DIS	CLOSURE	Filing Date	September 26, 2005			
STA	STATEMENT BY APPLICANT		First Named Inventor	SMITH, Dan				
	(llos os more ob			Art Unit	TBD			
(Use as many sheets as necessary)		Examiner Name	TBD					
Sheet	2	of	2	Attorney Docket Number	8114-009-WO-US	/		

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AGRAWAL et al. Antisense therapeutics: is it as simple as complementary base recognition? Molecular Medicine Today, 2000 Vol. 61-72-80.	
	Cite No.1	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. AGRAWAL et al. Antisense therapeutics: is it as simple as complementary

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Actor

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/550,722				
Filing Date	September 26, 2005				
First Named Inventor	SMITH, Dan				
Art Unit	TBD				
Examiner Name	TBD				
Attorney Docket Number	8114-009-WO-US				

			U. S. PATENT D			
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	 	US-	 			
	l	US-				
		US-				
		US-				
		US-				
	·	US-				
		US-				
		US-				
	 	US-				
	†	US-				
		US- ·				
		US-				
		US-	†			
		US-				
		US-				
		US-				
		US-	 			
		US-				
		US-				
	ı	l .	1		1	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Ī
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T'
						┢
						┢
						L
					1	

Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP7 Rec'd PCT/PTO 13 FEB 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TDANCAUTTAL	Application Number	ollection of information unless it displays a valid OMB control number. 10/550,722			
TRANSMITTAL	Filing Date	September 26, 2005			
FORM	First Named Inventor	SMITH, Dan TBD			
	Art Unit				
(to be used for all correspondence after initial filing)	Examiner Name	TBD			
Total Number of Pages in This Submission 7	Attorney Docket Number	8114-009-WO-US			

ENCLOSURES (Check all that apply)										
Am Ext Ext The control of the con	ctension of Time cpress Abandonr formation Disclosertified Copy of Focument(s) eply to Missing Promplete Application Reply to Missing Promplete Application	ed leclaration(s) Request ment Request sure Statement Priority	Rem	Drawing(s) Licensing-related Parelated Parelated Parelated Petition Petition to Convert to Provisional Applicate Power of Attorney, I Change of Corresponder Terminal Disclaimer Request for Refund CD, Number of CD(Landscape Ta	apers o a ion Revocation ondence Address		Appea of App Appea (Appea Propri Status Other below)	Allowance Communication to TC all Communication to Board heals and Interferences all Communication to TC all Notice, Brief, Reply Brief) hetary Information betary Letter Enclosure(s) (please Identify betary Pre-Paid Stamped Postcard		
		212111								
		SIGNA	TURE	OF APPLICANT	, ATTORNEY, C	OR AG	ENT			
Firm Name		YST LAW GOUP	, APC							
Signature	T	>M-								
Printed nar	me David M	David M. Kohn, J.D.								
Date	Februar	y 9, 2006			Reg. No.	53,15	50			
CERTIFICATE OF TRANSMISSION/MAILING										
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature										
Typed or printed name Christina Dueñas			S				Date	February 9, 2006		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.